International Agency for Research on Cancer (IARC) - Summaries & Evaluations


VOL.: 26 (1981) (p. 341)

5. Summary of Data Reported and Evaluation

5.1 Experimental data

No data on the carcinogenicity or teratogenicity of treosulphan in experimental animals were available to the Working Group.

The only available studies on chromosomal effects showed that it produces chromosomal aberrations in plants.

5.2 Human data

Treosulphan has had limited use since 1969, almost exclusively in the treatment of ovarian cancer.

The only epidemiological study indicates that use of this drug is followed by an increased risk of acute nonlymphocytic leukaemia.

5.3 Evaluation

There is sufficient evidence for the carcinogenicity of treosulphan in humans.

For definition of the italicized terms, see Preamble Evaluation.

Subsequent evaluation: Suppl. 7 (1987)

Last updated: 8 April 1998

    See Also:
       Toxicological Abbreviations
       Treosulphan  (IARC Summary & Evaluation, Supplement7, 1987)